GlassScriptPhysician profile
James A Goodson
NPI 1689677155
$3,412.45
in general payments reported to CMS, 2019-2025
20 companies · $744 in 2025
The $744 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $652 · 2020: $336 · 2021: $680 · 2022: $370 · 2023: $220 · 2024: $412 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,376.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,375.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $965.47 | 2019-2025 | Clareon, Rocklatan, Tryptyr |
| Sight Sciences, INC. | $545.19 | 2024-2025 | Omni Surgical System, Sion Surgical Instrument |
| Allergan, INC. | $341.26 | 2019-2021 | |
| Sun Pharmaceutical Industries INC. | $287.29 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $199.33 | 2019-2023 | |
| Bausch & Lomb Americas INC. | $193.74 | 2022-2025 | Vyzulta, Envista Mx60 Iol, Miebo |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $184.53 | 2019-2021 | |
| Shire North American Group INC | $122.72 | 2019 | |
| Abbvie INC. | $97.64 | 2023-2025 | |
| Kala Pharmaceuticals, INC. | $82.53 | 2019-2021 | |
| Rayner Intraocular Lenses Limited | $77.09 | 2022-2024 | Omidria, Rayone Aspheric, Rayone Emv |
| Amgen INC. | $74.06 | 2024-2025 | Tepezza |
| Omeros Corporation | $62.11 | 2020-2021 | |
| Rxsight INC | $53.26 | 2023 | Rxsight Injector Cartridge, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Notal Vision, INC. | $39.39 | 2025 | Foresee Home |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Oyster Point Pharma, INC. | $19.92 | 2025 | Tyrvaya, Ryzumvi |
| Eyevance Pharmaceuticals LLC | $19.15 | 2022 | |
| Apellis Pharmaceuticals, INC. | $17.33 | 2025 | Syfovre |
| Tarsus Pharmaceuticals, INC. | $15.37 | 2024 | Xdemvy |
| Horizon Therapeutics Plc | $15.07 | 2023 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Goodson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.